255 related articles for article (PubMed ID: 37507068)
21. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
22. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
[TBL] [Abstract][Full Text] [Related]
23. Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report.
Yamamoto M; Ikuta K; Toki Y; Hatayama M; Shindo M; Torimoto Y; Okumura T
Medicine (Baltimore); 2017 Sep; 96(36):e8001. PubMed ID: 28885361
[TBL] [Abstract][Full Text] [Related]
24. [Eosinophilia: hypereosinophilic syndrome vs. eosinophilic granulomatosis with polyangiitis].
Holle JU; Moosig F
Z Rheumatol; 2023 May; 82(4):307-320. PubMed ID: 37099180
[TBL] [Abstract][Full Text] [Related]
25. [Hypereosinophilic syndromes: pathogenic and therapeutic up-to-date].
Kahn JE; Grandpeix-Guyodo C; Ackermann F; Charles P; Legrand F; Blétry O
Rev Med Interne; 2010 Apr; 31(4):268-76. PubMed ID: 20303627
[TBL] [Abstract][Full Text] [Related]
26. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
Antoniu SA
Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
[TBL] [Abstract][Full Text] [Related]
27. Clinical and Biological Markers in Hypereosinophilic Syndromes.
Khoury P; Makiya M; Klion AD
Front Med (Lausanne); 2017; 4():240. PubMed ID: 29312946
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the diagnosis and treatment of hypereosinophilic syndromes.
Klion AD
Hematology Am Soc Hematol Educ Program; 2005; ():209-14. PubMed ID: 16304382
[TBL] [Abstract][Full Text] [Related]
29. Hypereosinophilic syndromes.
Roufosse FE; Goldman M; Cogan E
Orphanet J Rare Dis; 2007 Sep; 2():37. PubMed ID: 17848188
[TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive Review.
Nanagas VC; Kovalszki A
Clin Rev Allergy Immunol; 2019 Oct; 57(2):194-212. PubMed ID: 30003499
[TBL] [Abstract][Full Text] [Related]
31. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
[TBL] [Abstract][Full Text] [Related]
32. Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.
Requena G; van den Bosch J; Akuthota P; Kovalszki A; Steinfeld J; Kwon N; Van Dyke MK
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2125-2134. PubMed ID: 35470096
[TBL] [Abstract][Full Text] [Related]
33. Current and emerging biologic therapies targeting eosinophilic disorders.
Pitlick MM; Li JT; Pongdee T
World Allergy Organ J; 2022 Aug; 15(8):100676. PubMed ID: 35983569
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
Roufosse F; Kahn JE; Rothenberg ME; Wardlaw AJ; Klion AD; Kirby SY; Gilson MJ; Bentley JH; Bradford ES; Yancey SW; Steinfeld J; Gleich GJ;
J Allergy Clin Immunol; 2020 Dec; 146(6):1397-1405. PubMed ID: 32956756
[TBL] [Abstract][Full Text] [Related]
35. [The Hypereosinophilic Syndromes in Childhood].
Leu T; Simon HU; Hebestreit H; Kunzmann S
Klin Padiatr; 2015 Nov; 227(6-7):308-13. PubMed ID: 26267413
[TBL] [Abstract][Full Text] [Related]
36. [Hypereosinophilic syndrome--recent developments in diagnosis and treatment].
Hellmich B; Holl-Ulrich K; Gross WL
Dtsch Med Wochenschr; 2007 Sep; 132(37):1892-6. PubMed ID: 17823882
[TBL] [Abstract][Full Text] [Related]
37. Hypereosinophilic syndrome and proliferative diseases.
Ionescu MA; Wang L; Janin A
Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
[TBL] [Abstract][Full Text] [Related]
38. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
39. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré S; Gotlib J
Semin Cancer Biol; 2004 Aug; 14(4):307-15. PubMed ID: 15305431
[TBL] [Abstract][Full Text] [Related]
40. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
